OUR MARKETS(PLATELETS,RED CELLS,CONTAMINATES,NO WASHING,NEW PROTECTANT ELIMINA MINATION ON OF BLOOD D SHOR ORTAGES GES GLOBA BALL LLY Resea search and disco scovered ed in the sixtie ies s under er Militar itary Contr tract t with h Un Union on Car arbi bide e to elimin minat ate e shelf lf life e of Red d Cells. lls. Since e then we have e taken en it from om Red d Cell lls to Platele elets (shelf elf life e 5-6 days and d $30-50 50B B Market), ), White e Cells, ls, and Plasm sma. a. We can an impl mpleme ement t the Platele elet t market with thin in months hs using the existin sting cryo-protec ectant tant for bloo ood/s d/stem em cells. lls. Introd oducin ing a new w Cryo-protec ectan tant t that is alread ady FDA approved d for ot other er consu sumab mable le produc oducts. s. This s new w Cryo-Protec ectant tant will ll elimin minat ate e the need ed to be remo moved ed prior or to use. . The wa wash shing ing is an expen ensiv sive e toxic ic proc ocess ess whic ich will ll save e hospital itals/ s/blo blood od centers s millio lions. s. Our proc ocess ss will ll also so elimin minat ate e most st if not ot all contamin taminat ates es in bloo ood/s d/stem em cells, lls, i.e. . bac acter eria ia, parasit asites, es, HeP A-C, C, and Viruse ses. . We will ll strea eam m line e the whole ole donatio ation and managem agement t proc ocess ss. . All you do is donat ate e bloo ood. d. No separ arate e proc ocess ss to extr trac act t Platele elets, ts, White e Cells lls, , or Plasm sma. a. Significa icant t savi vings to hospital ital/b /bloo lood d cen enter ers. s.
Strategic partnering will be with companies like: Zipline.com. They use Drones for delivery of blood in Africa within minutes vs hours and days. Fremont Scientific has a device and inventory management system and a portable device (cost approx. &5K) that is no water base and portable. In most if not all cases the customer has the required freezers thereby eliminating any major capital investment to implement our technology. Thereby saving millions in re-curing costs. This is game changing technology that will change blood management as we know it today.
CURRENT MARKET ECONOMICS The market s which the process will have a major impact on: 1. Elimination of shelf life for all blood components: currently a $5.0B market 2. Elimination of shelf of platelets: currently a $3.0B market 3. Elimination of washing of cryoprotectant from blood and stem cells: potentially a $5B market
5 YEAR FINANCIAL PROJECTIONS C-Levelclone Financial Statement (Platelets) Platelets.New Protectant) ($000’s) 2018 2019 2020 2021 2022 Revenue 296,345,67 325,980,23 358,578,26 394,436,087 433,879,69 CC/G/S 88,903,701 97,794,071 107,573,47 118,330,826 130,163,90 Gross Margins 207,441,96 228,186,16 251,004,78 276,105,261 303,715,78 Operating Income Expenses 2,569,234 2,826,157 3,108,772 3,419,649.00 3,761,615 Profit Before Taxes 204,872,73 225,360,00 247,896,01 272,685,612.0 299,954,17
MARKE KET T SIZE ZE MODEL EL A PLATEL TELETS ETS UNITS TS DISOP SOPOSED OSED OF US (2011) ) 650,000 00 FMV of each h unit ($625) Value e of dispos osed d units( s(20 2011) 1) $406, 6,25 250, 0,00 000 Global al Market t $4,062, 2,500, 00,000 00 Global al Market t forward value ue 2018 18 ( growth th @ 2.5%PA) A) $482,903 03,587, 7,000 Assume ume 25% of Market
MA MARKE KET T SIZE ZE MODE DEL L A PLATELE TELETS TS Assume ume CL CLC C @25% of the market et $1, 1,121,05 059, 9,96 967 Royalty ty @10% $112,105, 05,997
Market et size e Model el B New w Prot otecta ctant nt Becker’s Hospital Review Hospit ital al rankings ngs by size ize # 1 w/ 2272 beds $74,248, 8,36 366 #100 w/674 4 beds ds $22,026, 26,144 #27 w/Joh ohn n Hopkins ns w/918 beds $ 30,000, 0,00 000 Mean n budge get t (1 and 100) $ 48,13 137, 7,255 55 US Blood od Mgt t budg dget et top 100 hospi pita tals s US $4,813, 3,725, 25,490 90 (the e data for the Platele elets ts and d New Prot otecta ctant nt taken en from the National ional Blood od Collecti ection on Utilization ization Repo port
Market t Size Discoun count t by 2/3 = reminder der 1/3 $ 1. 1.602, 2,970, 70,588 CLC process cess saving ng @ 15% $ 240,445, 45,588 88 Global alize ize @ 4 times es $961, 1,78 782, 2,35 352, 2,940 940 Process ess Royaltie alties s @7.5% % $ 72,13 133, 3,67 676 Tot otal al Roya yalti ties es Annual ally y $18 184,23 239, 9,67 673
BLOOD STORAGE DURATION & ADVERSE OUTCOMES IN CARDIAC SURGERY Clevela land nd clini nic c (Dr.Col Colle lenn nn Gorman n Koch) conduct ucted d the largest est blood storag orage e study udy to date . They found nd blood stored red more than n 14 days s are most t likely y to suffer r post t operati tive comp mplica cati tion n https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=0jF7k =0jF7kbIc6_ c6_M
KEY TAKE AWAYS • The technology is patented • The cryoprotectant used in the technology is currently FDA approved for other “HUMAN –INGESTED” consumable products • The cryoprotectant will replace DMSO/Glycerol which are the current standard protectants in use, each with significant documented disadvantages • The cryoprotectant is less expensive to purchase and the ratio of cryorotectant to be used is dramatically less (we estimate a reduction 400X’s in the amount required over current protocol) • Hospital and blood centers already have equipment to implement process. NO ADDITIONAL CAPITAL OUTLAY • Dramatic cost savings to hospital and blood centers (Data taken from ARC/WHO and National Blood Collection and Utilization Survey Report)
NATURAL DISASTERS /STORMS ON BLOOD SUPPLY Natural ral disast saster ers, s, storms orms have a m major impact mpact on the supply pply ava vailable. Our technol nology gy will eliminat minate shelf f life https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=Ze =Zet0vi t0viZ8a 8aVI
CREATING PLATELETS FROM BONE MARROW It is expensiv nsive e comp mplicat cated d and not ot alwa ways ys ava vailable. Our process ess you just st donate e blood with th our patent nted d Heat/Transf nsfer er rate. e. https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=ZX =ZXLLP LPWa9G 9Grg rg
CRYOPRESERVATION TECHNOLOGY WHAT ARE THE KEY DIFFERENCES IN CLC’S PROCESS COMPARED TO THE CURRENT STANDARD PROTOCOL? The specialty cryoprotectant used in this patented process is fundamentally different than currently used organic cryoprotectants (Glycerol and DMSO) and has the following distinct and unique characteristics: • It is a polymer, not organic, and therefore readily available and economically advantaged • It works at dramatically reducing quantum’s – for example, 400 times less than the currently used amount of Glycerol/DMSO • Critically, unlike current cryoprotecants , it does not need to be “washed” from the blood prior to transfusion, thereby eliminating an entire step in the commercial process of utilizing cryopreserved blood
Our Value e Proposi positi tion on Eliminate shelf life of all components of blood Draw blood as usual no separate station for Platelets No Glycerol which must be washed before use No DMSO which must be washed out before use : New Protectant- Polyvinyl Alcohol(PVA) FDA approved for other consumable products and will not have to washed prior to use Store whole blood until ready for use Eliminate shortages for all components Globally
AMERIC RICAN N ACADE DEMY MY OF BLOOD OOD BANKING KING PUBLIS ISHED HED IN 12-25 25-2016
WHAT IS CLC’S PROPREIETARY TECHNOLOGY? • Revolutionary advance in the science of cryopreservation of blood and its component parts, including platelets, using a proprietary process that is commercially feasible and economically superior to methods currently used in the United States and Europe • Significantly enhances the science of organ preservation and handling, thereby vastly improving the process of transplantation • Potentially broader and economic applicability to the current commercially utilized preservation process of high-end foods
PLATELETS • The preservation of platelets is extremely challenging • Effective shelf life is only 4- 6 days…even less when the actual processing is taken into account • CLC technology will permit the effective preservation of platelets indefinitely • Preliminary testing indicates that CLC’s unique process, together with the use of the identified protectant, results in the efficacious preservation of platelets for periods far in excess of today’s standard shelf life
Recommend
More recommend
